{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T17:15:56Z","timestamp":1788455756881,"version":"build-2803163510"},"reference-count":57,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:p>Autoimmune optic neuropathy (AON) encompasses a heterogeneous group of immune-mediated optic nerve inflammatory disorders, characterized by progressive or recurrent visual loss with or without optic disc edema, and distinct autoantibody profiles and neuroimaging features. This review synthesizes current knowledge on AON, highlighting key advances in the discovery of disease-specific biomarkers [eg, aquaporin-4 (AQP4)-IgG for NMOSD, myelin oligodendrocyte glycoprotein (MOG)-IgG for MOG-associated disease (MOGAD), and glial fibrillary acidic protein (GFAP)-IgG for astrocytopathy], while neuroimaging and optical coherence tomography (OCT) aid subtype differentiation. Therapeutically, acute management relies on high-dose intravenous methylprednisolone (IVMP), with plasma exchange for steroid-refractory cases; long-term maintenance is subtype-tailored. Prognosis varies by subtype, with MOG-ON showing better recovery than AQP4-ON, and CRMP5-IgG-associated ON carrying poor outcomes. Even with breakthroughs in pathogenetic understanding and targeted treatments, challenges reinforce the importance of continued interdisciplinary research to optimize AON management.<\/jats:p>","DOI":"10.1097\/iio.0000000000000596","type":"journal-article","created":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T04:00:15Z","timestamp":1766462415000},"page":"30-36","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Autoimmune Optic Neuropathy: Pathogenesis, Diagnosis, and Therapeutic Advances"],"prefix":"10.1097","volume":"66","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5385-9965","authenticated-orcid":false,"given":"Yan","family":"Yan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,12,23]]},"reference":[{"key":"R1-20251223","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/S1474-4422(22)00200-9","article-title":"Diagnosis and classification of optic neuritis","volume":"21","author":"Petzold","year":"2022","journal-title":"Lancet Neurol"},{"key":"R2-20251223","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1136\/jnnp.51.11.1381","article-title":"Autoimmune optic neuropathy: evaluation and treatment","volume":"51","author":"Kupersmith","year":"1988","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R3-20251223","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/0002-9394(82)90184-2","article-title":"Autoimmune retrobulbar optic neuritis","volume":"94","author":"Dutton","year":"1982","journal-title":"Am J Ophthalmol"},{"key":"R4-20251223","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1136\/bjo.2009.159350","article-title":"Clinical characteristics, diagnostic criteria and therapeutic outcomes in autoimmune optic neuropathy","volume":"93","author":"Frohman","year":"2009","journal-title":"Br J Ophthalmol"},{"key":"R5-20251223","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1007\/s11910-996-0020-0","article-title":"Autoimmune optic neuropathy","volume":"6","author":"Goodwin","year":"2006","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"pt 2","key":"R6-20251223","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1093\/brain\/awg045","article-title":"Chronic relapsing inflammatory optic neuropathy (CRION)","volume":"126","author":"Kidd","year":"2003","journal-title":"Brain"},{"key":"R7-20251223","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","article-title":"A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis","volume":"364","author":"Lennon","year":"2004","journal-title":"Lancet"},{"key":"R8-20251223","doi-asserted-by":"crossref","first-page":"e40","DOI":"10.1212\/NXI.0000000000000040","article-title":"Antibodies to myelin oligodendrocyte glycoprotein in bilateral and recurrent optic neuritis","volume":"1","author":"Ramanathan","year":"2014","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"R9-20251223","doi-asserted-by":"crossref","first-page":"e89","DOI":"10.1212\/NXI.0000000000000089","article-title":"MOG cell-based assay detects non-MS patients with inflammatory neurologic disease","volume":"2","author":"Waters","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"R10-20251223","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1001\/jamaneurol.2016.2549","article-title":"Autoimmune glial fibrillary acidic protein astrocytopathy: a novel meningoencephalomyelitis","volume":"73","author":"Fang","year":"2016","journal-title":"JAMA Neurol"},{"key":"R11-20251223","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1002\/ana.10587","article-title":"Paraneoplastic autoimmune optic neuritis with retinitis defined by CRMP-5-IgG","volume":"54","author":"Cross","year":"2003","journal-title":"Ann Neurol"},{"key":"R12-20251223","doi-asserted-by":"crossref","first-page":"578312","DOI":"10.1016\/j.jneuroim.2024.578312","article-title":"Papillitis associated with IgLON5 autoimmunity: a novel clinical phenotype","volume":"388","author":"Li","year":"2024","journal-title":"J Neuroimmunol"},{"key":"R13-20251223","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1001\/jama.2020.26858","article-title":"Diagnosis and treatment of multiple sclerosis: a review","volume":"325","author":"McGinley","year":"2021","journal-title":"JAMA"},{"key":"R14-20251223","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s10384-021-00840-w","article-title":"Current understanding of the epidemiologic and clinical characteristics of optic neuritis","volume":"65","author":"Nakazawa","year":"2021","journal-title":"Jpn J Ophthalmol"},{"key":"R15-20251223","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1001\/archopht.1991.01080120057025","article-title":"Optic Neuritis Study Group. The clinical profile of optic neuritis. Experience of the optic neuritis treatment trial. Optic Neuritis Study Group","volume":"109","year":"1991","journal-title":"Arch Ophthalmol"},{"key":"R16-20251223","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S1474-4422(22)00187-9","article-title":"Optic neuritis and autoimmune optic neuropathies: advances in diagnosis and treatment","volume":"22","author":"Bennett","year":"2023","journal-title":"Lancet Neurol"},{"key":"R17-20251223","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol"},{"key":"R18-20251223","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1155\/2006\/586306","article-title":"NMO-IgG: a specific biomarker for neuromyelitis optica","volume":"22","author":"Weinshenker","year":"2006","journal-title":"Dis Markers"},{"key":"R19-20251223","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"key":"R20-20251223","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s00401-013-1172-z","article-title":"Involvement of antibody-dependent cell-mediated cytotoxicity in inflammatory demyelination in a mouse model of neuromyelitis optica","volume":"126","author":"Ratelade","year":"2013","journal-title":"Acta Neuropathol"},{"key":"R21-20251223","doi-asserted-by":"crossref","first-page":"540156","DOI":"10.3389\/fneur.2020.540156","article-title":"AQP4-IgG and MOG-IgG related optic neuritis-prevalence, optical coherence tomography findings, and visual outcomes: a systematic review and meta-analysis","volume":"11","author":"Filippatou","year":"2020","journal-title":"Front Neurol"},{"key":"R22-20251223","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.msard.2015.06.003","article-title":"Specificity and sensitivity of aquaporin 4 antibody detection tests in patients with neuromyelitis optica: a meta-analysis","volume":"4","author":"Ruiz-Gaviria","year":"2015","journal-title":"Mult Scler Relat Disord"},{"key":"R23-20251223","doi-asserted-by":"crossref","first-page":"e231","DOI":"10.1212\/NXI.0000000000000231","article-title":"Clinical utility of testing AQP4-IgG in CSF: Guidance for physicians","volume":"3","author":"Majed","year":"2016","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"R24-20251223","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s00415-024-12827-x","article-title":"Magnetic resonance imaging-based biomarkers of multiple sclerosis and neuromyelitis optica spectrum disorder: a systematic review and meta-analysis","volume":"272","author":"Mirmosayyeb","year":"2024","journal-title":"J Neurol"},{"key":"R25-20251223","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1111\/ene.15178","article-title":"Chiasmatic lesions on conventional magnetic resonance imaging during the first event of optic neuritis in patients with neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein-associated disease in a Latin American cohort","volume":"29","author":"Carnero Contentti","year":"2022","journal-title":"Eur J Neurol"},{"key":"R26-20251223","doi-asserted-by":"crossref","first-page":"3938","DOI":"10.1093\/brain\/awad122","article-title":"Diagnostic implications of MOG-IgG detection in sera and cerebrospinal fluids","volume":"146","author":"Matsumoto","year":"2023","journal-title":"Brain"},{"key":"R27-20251223","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/S1474-4422(22)00431-8","article-title":"Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria","volume":"22","author":"Banwell","year":"2023","journal-title":"Lancet Neurol"},{"key":"R28-20251223","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1038\/s41433-024-03108-y","article-title":"MOG antibody-associated optic neuritis","volume":"38","author":"Jeyakumar","year":"2024","journal-title":"Eye (Lond)"},{"key":"R29-20251223","doi-asserted-by":"crossref","first-page":"103693","DOI":"10.1016\/j.autrev.2024.103693","article-title":"MOGAD: a comprehensive review of clinicoradiological features, therapy and outcomes in 4699 patients globally","volume":"24","author":"Trewin","year":"2025","journal-title":"Autoimmun Rev"},{"key":"R30-20251223","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1177\/13524585241240420","article-title":"Optic chiasm involvement in multiple sclerosis, aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein-associated disease","volume":"30","author":"Bianchi","year":"2024","journal-title":"Mult Scler"},{"key":"R31-20251223","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1097\/WCO.0000000000000676","article-title":"Autoimmune glial fibrillary acidic protein astrocytopathy","volume":"32","author":"Kunchok","year":"2019","journal-title":"Curr Opin Neurol"},{"key":"R32-20251223","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1212\/NXI.0000000000200146","article-title":"Visual System Involvement in Glial Fibrillary Acidic Protein Astrocytopathy: Two Case Reports and a Systematic Literature Review.","volume":"10","author":"Greco","year":"2023","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"R33-20251223","doi-asserted-by":"crossref","first-page":"e16284","DOI":"10.1111\/ene.16284","article-title":"Clinical and neuroimaging phenotypes of autoimmune glial fibrillary acidic protein astrocytopathy: a systematic review and meta-analysis","volume":"31","author":"Hagbohm","year":"2024","journal-title":"Eur J Neurol"},{"key":"R34-20251223","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.4103\/1673-5374.371400","article-title":"An overview on CV2\/CRMP5 antibody-associated paraneoplastic neurological syndromes","volume":"18","author":"Wang","year":"2023","journal-title":"Neural Regen Res"},{"key":"R35-20251223","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ophtha.2019.09.012","article-title":"Collapsin response-mediator protein 5-associated retinitis, vitritis, and optic disc edema","volume":"127","author":"Cohen","year":"2020","journal-title":"Ophthalmology"},{"key":"R36-20251223","doi-asserted-by":"crossref","first-page":"e103","DOI":"10.1212\/WNL.0000000000004803","article-title":"Autoimmune CRMP5 neuropathy phenotype and outcome defined from 105 cases","volume":"90","author":"Dubey","year":"2018","journal-title":"Neurology"},{"key":"R37-20251223","doi-asserted-by":"crossref","first-page":"1163615","DOI":"10.3389\/fneur.2023.1163615","article-title":"Collapsin response mediator protein 5-associated optic neuropathy: clinical characteristics, radiologic clues, and outcomes","volume":"14","author":"Yan","year":"2023","journal-title":"Front Neurol"},{"key":"R38-20251223","doi-asserted-by":"crossref","first-page":"19536","DOI":"10.1038\/s41598-021-97768-5","article-title":"Spatiotemporal expression of IgLON family members in the developing mouse nervous system","volume":"11","author":"Fearnley","year":"2021","journal-title":"Sci Rep"},{"key":"R39-20251223","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1097\/WNO.0000000000002114","article-title":"Anti-immunoglobulin-like cell adhesion molecule-5 (IgLON5) associated neurological disease presenting with bilateral intraocular optic neuritis as an initial presentation: expanding clinical phenotype of the disease","volume":"45","author":"Varma-Doyle","year":"2025","journal-title":"J Neuroophthalmol"},{"key":"R40-20251223","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s00415-013-6957-4","article-title":"Chronic relapsing inflammatory optic neuropathy: a systematic review of 122 cases reported","volume":"261","author":"Petzold","year":"2014","journal-title":"J Neurol"},{"key":"R41-20251223","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1186\/s12974-018-1335-x","article-title":"Chronic relapsing inflammatory optic neuropathy (CRION): a manifestation of myelin oligodendrocyte glycoprotein antibodies","volume":"15","author":"Lee","year":"2018","journal-title":"J Neuroinflammation"},{"key":"R42-20251223","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1097\/ICU.0000000000000804","article-title":"Chronic relapsing inflammatory optic neuropathy (CRION)","volume":"32","author":"Mukharesh","year":"2021","journal-title":"Curr Opin Ophthalmol"},{"key":"R43-20251223","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1097\/WNO.0b013e31829f39f1","article-title":"The retinal nerve fiber layer of patients with neuromyelitis optica and chronic relapsing optic neuritis is more severely damaged than patients with multiple sclerosis","volume":"33","author":"Bichuetti","year":"2013","journal-title":"J Neuroophthalmol"},{"key":"R44-20251223","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1056\/NEJM199202273260901","article-title":"A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group","volume":"326","author":"Beck","year":"1992","journal-title":"N Engl J Med"},{"key":"R45-20251223","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/ana.24554","article-title":"Neuromyelitis optica: evaluation of 871 attacks and 1,153 treatment courses","volume":"79","author":"Kleiter","year":"2016","journal-title":"Ann Neurol"},{"key":"R46-20251223","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1186\/s12974-016-0718-0","article-title":"MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome","volume":"13","author":"Jarius","year":"2016","journal-title":"J Neuroinflammation"},{"key":"R47-20251223","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.ajo.2023.02.013","article-title":"Visual outcomes following plasma exchange for optic neuritis: an international multicenter retrospective analysis of 395 optic neuritis attacks","volume":"252","author":"Chen","year":"2023","journal-title":"Am J Ophthalmol"},{"key":"R48-20251223","doi-asserted-by":"crossref","first-page":"102325","DOI":"10.1016\/j.msard.2020.102325","article-title":"Intravenous immunoglobulin for acute attacks in neuromyelitis optica spectrum disorders (NMOSD)","volume":"44","author":"Li","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"R49-20251223","doi-asserted-by":"crossref","first-page":"e200124","DOI":"10.1212\/NXI.0000000000200124","article-title":"International Delphi consensus on the management of AQP4-IgG+ NMOSD: recommendations for eculizumab, inebilizumab, and satralizumab","volume":"10","author":"Paul","year":"2023","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"R50-20251223","doi-asserted-by":"crossref","first-page":"106311","DOI":"10.1016\/j.msard.2025.106311","article-title":"Ravulizumab and other complement inhibitors for the treatment of autoimmune disorders","volume":"95","author":"Vieira","year":"2025","journal-title":"Mult Scler Relat Disord"},{"key":"R51-20251223","doi-asserted-by":"crossref","first-page":"e913","DOI":"10.1212\/NXI.0000000000000913","article-title":"Anti-CD20 therapies and pregnancy in neuroimmunologic disorders: a cohort study from Germany","volume":"8","author":"Kumpfel","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"R52-20251223","doi-asserted-by":"crossref","first-page":"885218","DOI":"10.3389\/fneur.2022.885218","article-title":"Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): a review of clinical and MRI features, diagnosis, and management","volume":"13","author":"Sechi","year":"2022","journal-title":"Front Neurol"},{"key":"R53-20251223","doi-asserted-by":"crossref","first-page":"102251","DOI":"10.1016\/j.msard.2020.102251","article-title":"Treatment of MOG-IgG-associated disorder with rituximab: an international study of 121 patients","volume":"44","author":"Whittam","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"R54-20251223","doi-asserted-by":"crossref","first-page":"2802","DOI":"10.3389\/fimmu.2018.02802","article-title":"Autoimmune glial fibrillary acidic protein astrocytopathy: a review of the literature","volume":"9","author":"Shan","year":"2018","journal-title":"Front Immunol"},{"key":"R55-20251223","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/cei.13630","article-title":"Magnetic resonance imaging in neuromyelitis optica spectrum disorder","volume":"206","author":"Clarke","year":"2021","journal-title":"Clin Exp Immunol"},{"key":"R56-20251223","doi-asserted-by":"crossref","first-page":"105729","DOI":"10.1016\/j.msard.2024.105729","article-title":"Longitudinal change of serum NfL as disease activity biomarker candidate in MOGAD: a descriptive cohort study","volume":"88","author":"Schindler","year":"2024","journal-title":"Mult Scler Relat Disord"},{"key":"R57-20251223","doi-asserted-by":"crossref","first-page":"105518","DOI":"10.1016\/j.msard.2024.105518","article-title":"Isolated myelin oligodendrocyte glycoprotein antibody-associated optic neuritis in adults: the importance of age of onset and prognosis-related radiological features","volume":"85","author":"Zhao","year":"2024","journal-title":"Mult Scler Relat Disord"}],"container-title":["International Ophthalmology Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/IIO.0000000000000596","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T19:05:39Z","timestamp":1785783939000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/IIO.0000000000000596"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,23]]},"references-count":57,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/iio.0000000000000596","relation":{},"ISSN":["0020-8167","1536-9617"],"issn-type":[{"value":"0020-8167","type":"print"},{"value":"1536-9617","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,23]]},"assertion":[{"value":"2025-08-27","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-13","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}